Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.

Daniele G, Iozzo P, Molina-Carrion M, Lancaster J, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Gastaldelli A

Diabetes26 Jun 2015Cited by 54 (Europe PMC)

PMID26116695PMCIDPMC6908417DOI10.2337/db14-1718PepBankPUB-26116695

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In male subjects undergoing OGTT, exenatide reduced glucose absorption during the early period versus placebo.
In plain wordsIn men, exenatide reduced early glucose absorption during a glucose test compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose absorption rate
Study
n = 15
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneous · single injectionAs given in this study (human).
Measurements
RaO0-60 min
4.6 μmol/min ⋅ kg
exenatide
RaO0-60 min
13.1 μmol/min ⋅ kg
placebo
Source sentences
Summary
Exenatide reduced RaO0-60 min (4.6 ± 1.4 vs. 13.1 ± 1.7 μmol/min ⋅ kg) and decreased the rise in mean glucose0-60 min (107 ± 6 vs. 138 ± 8 mg/dL) and insulin0-60 min (17.3 ± 3.1 vs. 24.7 ± 3.8 mU/L).
1 context sentence(design, population, supporting numbers)
Summary · context
In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).
Report a problemFND-2611669501
02HumanRandomized controlled trialEfficacy outcome
In male subjects undergoing OGTT, exenatide decreased the early rise in mean glucose versus placebo.
In plain wordsIn men, exenatide reduced the early glucose rise during a glucose test compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMean glucose rise
Study
n = 15
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneous · single injectionAs given in this study (human).
Measurements
mean glucose0-60 min
107 mg/dL
exenatide
mean glucose0-60 min
138 mg/dL
placebo
Source sentences
Summary
Exenatide reduced RaO0-60 min (4.6 ± 1.4 vs. 13.1 ± 1.7 μmol/min ⋅ kg) and decreased the rise in mean glucose0-60 min (107 ± 6 vs. 138 ± 8 mg/dL) and insulin0-60 min (17.3 ± 3.1 vs. 24.7 ± 3.8 mU/L).
1 context sentence(design, population, supporting numbers)
Summary · context
In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).
Report a problemFND-2611669502
03HumanRandomized controlled trialMechanism
In male subjects undergoing OGTT, exenatide decreased the early insulin rise versus placebo.
In plain wordsIn men, exenatide reduced the early insulin rise during a glucose test compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulin rise
Study
n = 15
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg · subcutaneous · single injectionAs given in this study (human).
Measurements
insulin0-60 min
17.3 mU/L
exenatide
insulin0-60 min
24.7 mU/L
placebo
Source sentences
Summary
Exenatide reduced RaO0-60 min (4.6 ± 1.4 vs. 13.1 ± 1.7 μmol/min ⋅ kg) and decreased the rise in mean glucose0-60 min (107 ± 6 vs. 138 ± 8 mg/dL) and insulin0-60 min (17.3 ± 3.1 vs. 24.7 ± 3.8 mU/L).
1 context sentence(design, population, supporting numbers)
Summary · context
In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).
Report a problemFND-2611669503
04HumanRandomized controlled trialMechanism
In male subjects, exenatide increased cerebral glucose metabolism in areas related to glucose homeostasis, appetite and food reward versus placebo.
In plain wordsIn men, exenatide increased glucose metabolism in brain areas related to glucose control, appetite and food reward compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRegional cerebral glucose metabolic rate
Study
n = 15
Comparator
placebo
Outcome group
Metabolic pathways and metabolomics · Nervous system and cognition
Studied dose
5 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
Exenatide increased CMRglu in areas of the brain related to glucose homeostasis, appetite, and food reward, despite lower plasma insulin concentrations, but reduced glucose uptake in the hypothalamus.
1 context sentence(design, population, supporting numbers)
Summary · context
In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).
Report a problemFND-2611669504
05HumanRandomized controlled trialMechanism
In male subjects, exenatide reduced hypothalamic glucose uptake versus placebo.
In plain wordsIn men, exenatide reduced glucose uptake in the hypothalamus compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHypothalamic glucose uptake
Study
n = 15
Comparator
placebo
Outcome group
Metabolic pathways and metabolomics · Nervous system and cognition
Studied dose
5 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
Exenatide increased CMRglu in areas of the brain related to glucose homeostasis, appetite, and food reward, despite lower plasma insulin concentrations, but reduced glucose uptake in the hypothalamus.
1 context sentence(design, population, supporting numbers)
Summary · context
In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).
Report a problemFND-2611669505

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialMechanism
In male subjects after exenatide, decreased early glucose absorption was inversely correlated with cerebral glucose metabolism.
In plain wordsIn men after exenatide, lower early glucose absorption was inversely linked to brain glucose metabolism.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableGlucose absorption association with cerebral metabolism
Study
n = 15
Outcome group
Metabolic pathways and metabolomics · Nervous system and cognition
Source sentences
Summary
Decreased RaO0-60 min after exenatide was inversely correlated to CMRglu.
1 context sentence(design, population, supporting numbers)
Summary · context
In 15 male subjects with HbA1c of 5.7 ± 0.1%, fasting glucose of 114 ± 3 mg/dL, and 2-h glucose of 177 ± 11 mg/dL, exenatide (5 μg) or placebo was injected in double-blind, randomized fashion subcutaneously 30 min before an oral glucose tolerance test (OGTT).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2611669506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01588418

Acute Effect of Exenatide on Brain Glucose Metabolism

The University of Texas Health Science Center at San Antonion = 15Jul 2010 to Jul 2015

Impaired Glucose Tolerance (IGT) · Diabetes

Trial page ClinicalTrials.govUpdated 24 Nov 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.